XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue:        
Total revenue $ 46,333 $ 40,134 $ 152,877 $ 120,614
Operating costs and expenses:        
Cost of goods sold $ 5,295 $ 4,243 $ 36,227 $ 13,441
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 21,708 $ 61,194 $ 94,206 $ 231,158
Selling, general and administrative 17,554 25,573 62,650 91,029
Restructuring charge 18,554 12,606 18,554 12,606
Total operating costs and expenses 63,111 103,616 211,637 348,234
Loss from operations (16,778) (63,482) (58,760) (227,620)
Interest and other, net        
Interest expense (4,994) (5,022) (14,774) (10,464)
Interest income and other income (expenses), net 3,802 4,296 5,092 7,984
Total interest and other, net (1,192) (726) (9,682) (2,480)
Loss before income taxes (17,970) (64,208) (68,442) (230,100)
Provision for (benefit from) income taxes 12 84 (217) (77)
Investment income in unconsolidated variable interest entity 898 677 2,664 2,023
Net loss $ (17,084) $ (63,615) $ (65,561) $ (228,000)
Net loss per share - basic $ (0.17) $ (0.65) $ (0.66) $ (2.35)
Net loss per share - diluted $ (0.17) $ (0.65) $ (0.66) $ (2.35)
Weighted average number of common shares used to calculate net loss per share:        
Basic 100,515 98,245 99,780 96,901
Diluted 100,515 98,245 99,780 96,901
License Revenue [Member]        
Revenue:        
Total revenue $ 0 $ 2,649 $ 0 $ 9,649
Development and Other Revenue [Member]        
Revenue:        
Total revenue 385 6,775 1,532 15,825
Product Revenue, Net [Member]        
Revenue:        
Total revenue 46,210 29,390 126,391 77,439
Drug Product Revenue, Net [Member]        
Revenue:        
Total revenue $ (262) $ 1,320 $ 24,954 $ 17,701